CRON241018C5500
- 0.03
- 0.000.00%
Cronos Group Newsroom
Cronos Group Inc. (CRON): A Bull Case Theory
Cannabis Flower? No, Thanks: Canadians Shift To Pre-Rolls & Vapes As Market Eyes C$5.47B
Cannabis Stocks React To Trump's Marijuana Comments: See Which Ones Posted Solid Gains
Marijuana Stock Movers For September 9, 2024
Trump's Marijuana Support Could Ignite Stock Surge – Are You Positioned To Benefit?
American Views on Marijuana Effects Worsening: Gallup
Lord Jones Live Resin Vapes and Ice Water Hash Pre-Rolls Now Available Across Canada
Shares of Cannabis Stocks Are Trading Lower After the DEA Announced a Delay on Its Final Ruling on Cannabis Rescheduling Until After the November Presidential Election.
Cannabis Stocks Drop Sharply as DEA Sets Drug-rescheduling Hearing After November Election
Why Cronos Group Stock Is Sinking Today
Cannabis Stocks Drop as DEA Sets Drug-rescheduling Hearing After November Election
The hearing on the reclassification of cannabis is approaching, and both US cannabis stocks and ETFs are under pressure.
The upcoming open hearing on December 2nd by the US Drug Enforcement Administration has attracted widespread attention from the market, and aims to discuss the proposal to reclassify marijuana.
DEA Sets Hearing on Cannabis Rescheduling and Delays Decision Until After the Election
Cannabis Stocks on Watch as DEA Sets Hearing on Marijuana Rescheduling
Ubiquiti, Red Robin And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Cronos Rises 4% After Crypto.com Announces Partnership With UEFA Champions League
Canopy Growth Posts Wider-than-expected Loss as Revenue Falls, but Company Sees Growth Opportunities in U.S. Markets
Express News | Cronos Group Inc : BofA Global Research Cuts Price Objective to $2.30 From $2.75
Cronos Group: Caution Advised Amid Regulatory Uncertainties and Sector Re-rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cronos Group (CRON), Relay Therapeutics (RLAY) and Century Therapeutics (IPSC)